(12) Patent Application Publication (10) Pub. No.: US 2016/0213673 A1 BARTOS Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2016/0213673 A1 BARTOS Et Al US 20160213673A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0213673 A1 BARTOS et al. (43) Pub. Date: Jul. 28, 2016 (54) ENDURANCE FORMULATION AND USE Publication Classification (71) Applicant: GLANBLA NUTRITIONALS (51) Int. Cl. (IRELAND) LIMITED, KILKENNY A613 L/522 (2006.01) (IE) A63L/98 (2006.01) A2.3L 2/52 (2006.01) (72) Inventors: Jeremy D. BARTOS, San Marcos, CA A63L/216 (2006.01) (US); Elaine DRUMMOND, Carlsbad, (52) U.S. Cl. CA (US) CPC ............. A6 IK3I/522 (2013.01); A61 K3I/216 (2013.01); A61 K3I/198 (2013.01); A23L I/3051 (2013.01); A23L 2/52 (2013.01); A23L (21) Appl. No.: 15/003,130 I/302 (2013.01); A23L 1/304 (2013.01); A23L I/30 (2013.01); A23 V 2002/00 (2013.01) 22) Filed: Jan. 21, 2016 (57) ABSTRACT (22) Filed: al. Al The present disclosure provides compositions and formula tions containing dihydrocapsiate, caffeine and arginine as Related U.S. Application Data well as methods of making and using the compositions and formulations. The compositions and formulations of the (60) Provisional application No. 62/108.207, filed on Jan. present disclosure increase human endurance during times of 27, 2015. physical activity. US 2016/0213673 A1 Jul. 28, 2016 ENDURANCE FORMULATION AND USE 0010 Capsinoids such as dihydrocapsiate exert similar 0001. The present application claims benefit of U.S. Pro thermogenic and lipolytic effects as the red pepper compound visional Patent Application No. 62/108.207, filed Jan. 27. capsaicin but without noxious sensations of pungency or 2015, the entire contents of which is incorporated herein by "hotness.” In addition, dihydrocapsiate does not cause reference. increases in blood pressure and heart rate like those attributed 0002 The present disclosure provides compositions and to capsaicin ingestion. The thermogenic and lipolytic effects formulations containing dihydrocapsiate, caffeine and argin of dihydrocapsiate (and all other capsaicins and capsinoids) ine as well as methods of making and using the compositions are mediated through the Transient Receptor Potential Vanil and formulations. The compositions and formulations of the loid 1 (TRPV1) receptors throughout the gastrointestinal present disclosure increase human endurance during times of tract, which in turn are linked with the sympathetic nervous physical activity. system (SNS). When activated, they increase SNS activity 0003. The compositions and formulations of the present which results in the downstream activation of uncoupling disclosure are believed to increase or enhance endurance proteins UCP-1, UCP-2, and UCP-3. when ingested by sparing glycogen stores, increasing aerobic 0011. Of particular importance for endurance is UCP-2 activity over anaerobic activity during times of physical activ and UCP-3, the latter of which is expressed in the skeletal ity and thereby reducing metabolite buildup that would nor muscle of all mammals and plays a role in the transport of free mally lead to exhaustion and limitations on endurance by a fatty acids. UCP-2 is primarily expressed in adipocytes and person not ingesting a composition or formulation of the plays a key role in lipolysis, which is the release of free fatty present disclosure. acids from their storage in adipocytes. This release is trig 0004 Compositions and formulations of the present dis gered as the body is searching for a fuel store to induce closure enhance endurance when ingested before or during, thermogenesis brought on by the TRPV-1 receptor activation or before and during physical exertion. Increasing endurance, (for example, in shivering). or the amount of time the body can work out, for example 0012 Free fatty acids can be utilized as a fuel source in running longer distances or for longer time, increasing num endurance training as well, and since UCP-3 is expressed in ber of reps of workout, etc., is an increasingly important focus skeletal muscle and helps transport free fatty acids, it is rea of sports nutrition. sonable to believe that it will help increase free fatty acid 0005. A focus of the presently disclosure technology is uptake by the muscles. enhancing endurance by increasing the sparing of glycogen 0013. In one animal study (“Upregulation of uncoupling stores, forcing aerobic activity as compared to anaerobic, proteins by oral administration of capsiate, a nonpungent increasing vasodilation, and reducing the build-up of metabo capsaicin analog J Appl Physiol. 2003 December; 95(6): lites that can lead to the feeling of exhaustion during and after 2408-15), UCP3 mRNA expression in skeletal muscle physical activity. occurred within minutes of capsinoid ingestion and persisted 0006. The combination of dihydrocapsiate, caffeine and for 2 hours. A separate animal study ("Capsiate, a Nonpun arginine provided in compositions and formulations of the gent Capsaicin Analog, Increases Endurance Swimming present disclosure provide a unique combination designed to Capacity of Mice by Stimulation of Vanilloid Receptors' enhance endurance via one or more of these mechanisms. Biosci Biotechnol Biochem. 2006 April; 70(4):774-81) dem 0007 Two of the main mechanisms for ATP synthesis are onstrated that mice taking capsiate were able to Swim signifi aerobic respiration (glycolysis, citric acid cycle, oxidative cantly longer than mice who hadn't taken capsiate. In addi phosphorylation, etc.) and anaerobic respiration (glycolysis tion, after 30 min of Swimming, the residual glycogen in the only). Aerobic respiration pathways occur in an oxygen-rich gastrocnemius muscle was higher, the serum free fatty acid state, have a more efficient output of ATP (36-38 ATP/glu concentration tended to be higher, and the serum lactic acid cose), and are typically associated with endurance exercise. concentration was significantly lower in the capsiate-admin Anaerobic respiration occurs in an oxygen poor environment, istered mice. has less efficient output of ATP (2 ATP/glucose), and is typi 0014. This suggests that the capsiate increased the release cally associated with intense exercise (weightlifting, sprint of free fatty acids, which UCP-3 brought to the muscle to use ing, etc.). Anaerobic respiration is also much quicker than as fuel, sparing glycogen stores for later and thus lengthening aerobic respiration (because it is only going through the gly the Swimming time. This allows for increased aerobic exer colysis), and is only utilized by muscle cells. cise and delayed anaerobic exercise. This mechanism of 0008. In theory, if the body can endure longer periods of action was Subsequently proved in the same experiment when anaerobic respiration than aerobic respiration, or if it can researchers demonstrated significantly higher oxygen con utilize free fatty acids as fuel instead of glucose, it will help Sumption (aerobic) and fat oxidation (using fat as fuel) with extend the short-term, high intensity activities associated reduced carbohydrate oxidation (glycogen sparing) follow with weight training. Once glycogen stores are used up, ing capsiate administration. fatigue will also set in. Glycogen sparing is maximized with 0015 While these studies were performed using capsiate the use of non-carbohydrates as a source of energy during and not dihydrocapsiate, a previous study (Assessment of the exercise so that the depletion of muscle glycogen is delayed. biological similarity of three capsaicin analogs (Capsinoids) Glycogen is spared because the body burns fats for energy, found in non-pungent chili pepper (CH-19 Sweet) fruits' making a greater contribution to an athlete’s efforts during the Biosci Biotechnol Biochem 2010; 74(2):274-8; and “Activa initial stages of a race. This leaves more glycogen for the later tion of transient receptor potential A1 by a non-pungent cap stages of racing or exercise, for example, and muscle fatigue saicin-like compound, capsiate; Br J Pharmacol' 2012 will be delayed. March; 165(5): 1476-86) have shown that capsiate and dihy 0009 Increasing vasodilation will also increase the rate of drocapsiate have similar rates of TRVP-1 activation, Suggest oxygen and glucose to the muscles, lengthening the time of ing that dihydrocapsiate will have a similar effect on endur aerobic respiration and further sparing glycogen stores. aCC. US 2016/0213673 A1 Jul. 28, 2016 0016 Respiratory quotient (RQ) is a simple measurement jugates with molecules Such as resveratrol, and in the form of of the ratio of carbon dioxide eliminated to oxygen con Arginine Silicate Inositol (ASI). Arginine is necessary for the Sumed. This is particularly helpful when calculating an synthesis of creatine in the body. Creatine is thought to build organism's basal metabolic rate from carbon dioxide produc lean muscle mass and assist with short high intensity bursts tion, which is easily measured when the organism exhales. (weightlifting, sprinting, etc.) Creatine has also been shown Based on the respiratory quotient one can determine if the to induce glycogensparing in animal studies. Finally, creatine organism’s primary energy source is carbohydrates (RQ is known to assist with water retention, and studies in con around 1) Such as Sugar or if it is primarily from fats (RQ junction with glycerol Supplementation have demonstrated a around 0.7). A mixed diet offat and carbohydrate results in an measurable effect on hyperhydration and endurance (“The average value between 0.7 and 1 and therefore the lower the effects of creatine and glycerol hyperhydration on running RQ the more likely the source of energy is from fats. Com economy in well trained
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Properties of Chemically Oxidized Kininogens*
    Vol. 50 No. 3/2003 753–763 QUARTERLY Properties of chemically oxidized kininogens*. Magdalena Nizio³ek, Marcin Kot, Krzysztof Pyka, Pawe³ Mak and Andrzej Kozik½ Faculty of Biotechnology, Jagiellonian University, Kraków, Poland Received: 30 May, 2003; revised: 01 August, 2003; accepted: 11 August, 2003 Key words: bradykinin, N-chlorosuccinimide, chloramine-T, kallidin, kallikrein, reactive oxygen species Kininogens are multifunctional proteins involved in a variety of regulatory pro- cesses including the kinin-formation cascade, blood coagulation, fibrynolysis, inhibi- tion of cysteine proteinases etc. A working hypothesis of this work was that the prop- erties of kininogens may be altered by oxidation of their methionine residues by reac- tive oxygen species that are released at the inflammatory foci during phagocytosis of pathogen particles by recruited neutrophil cells. Two methionine-specific oxidizing reagents, N-chlorosuccinimide (NCS) and chloramine-T (CT), were used to oxidize the high molecular mass (HK) and low molecular mass (LK) forms of human kininogen. A nearly complete conversion of methionine residues to methionine sulfoxide residues in the modified proteins was determined by amino acid analysis. Production of kinins from oxidized kininogens by plasma and tissue kallikreins was significantly lower (by at least 70%) than that from native kininogens. This quenching effect on kinin release could primarily be assigned to the modification of the critical Met-361 residue adja- cent to the internal kinin sequence in kininogen. However, virtually no kinin could be formed by human plasma kallikrein from NCS-modified HK. This observation sug- gests involvement of other structural effects detrimental for kinin production. In- deed, NCS-oxidized HK was unable to bind (pre)kallikrein, probably due to the modifi- cation of methionine and/or tryptophan residues at the region on the kininogen mole- cule responsible for the (pro)enzyme binding.
    [Show full text]
  • Sized Neuropeptides
    M ETHODS IN MOLECULAR BIOLOGY™ Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Neuropeptides Methods and Protocols Edited by Adalberto Merighi Dipartimento di Morfofisiologia Veterinaria, Università degli Studi di Torino, Grugliasco, TO, Italy; Istituto Nazionale di Neuroscienze (INN), Università degli Studi di Torino, Grugliasco, TO, Italy Editor Adalberto Merighi Dipartimento di Morfofisiologia Veterinaria Università degli Studi di Torino and Istituto Nazionale di Neuroscienze (INN) Università degli Studi di Torino Grugliasco, TO, Italy [email protected] Please note that additional material for this book can be downloaded from http://extras.springer.com ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-61779-309-7 e-ISBN 978-1-61779-310-3 DOI 10.1007/978-1-61779-310-3 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011936011 © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,039,660 Leonard Et Al
    United States Patent (19) 11 Patent Number: 5,039,660 Leonard et al. (45. Date of Patent: Aug. 13, 1991 54 PARTIALLY FUSED PEPTIDE PELLET 4,667,014 5/1987 Nestor, Jr. et al. ................. 514/800 4,801,577 / 1989 Nestor, Jr. et al. ................. 54/800 75 Inventors: Robert J. Leonard, Lynnfield, Mass.; S. Mitchell Harman, Ellicott City, Primary Examiner-Lester L. Lee Md. Attorney, Agent, or Firm-Wolf, Greenfield & Sacks 73 Assignee: Endocon, Inc., South Walpole, Mass. (57) ABSTRACT 21 Appl. No.: 163,328 A bioerodible pellet capable of administering an even 22 Filed: Mar. 2, 1988 and continuous dose of a peptide over a period of up to a year, when subcutaneously implanted, is provided. (51) Int. Cl’.............................................. C07K 17/08 (52 U.S.C. .......................................... 514/8; 514/12; The bioerodible implant is a partially-fused pellet, 514/14: 514/15; 514/16; 514/17; 514/18; which pellet has a peptide drug homogeneously-bound 514/19; 514/800 in a matrix of a melted and recrystallized, nonpolymer Field of Search ................... 514/8, 12, 14, 15, 16, carrier. Preferably, the nonpolymer carrier is a steroid (58) and in particular is cholesterol or a cholesterol deriva 514/17, 18, 19, 800 tive. In one embodiment, the peptide drug is growth (56) References Cited hormone-releasing hormone. A method for making the U.S. PATENT DOCUMENTS bioerodible pellet also is provided. 4,164,560 8/1979 Folkman et al. .................... 424/427 '4,591,496 5/1986 Cohen et al. .......................... 424/78 13 Claims, 4 Drawing Sheets U.S. Patent Aug.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Akhtar Saeed Medical and Dental College, Lhr
    STUDY GUIDE PHARMACOLOGY 3RD YEAR MBBS 2021 AKHTAR SAEED MEDICAL AND DENTAL COLLEGE, LHR 1 Table of contents s.No Topic Page No 1. Brief introduction about study guide 03 2. Study guide about amdc pharmacology 04 3. Learning objectives at the end of each topic 05-21 4. Pharmacology classifications 22-59 5. General pharmacology definitions 60-68 6. Brief introduction about FB PAGE AND GROUP 69-70 7. ACADEMIC CALENDER (session wise) 72 2 Department of pharmacology STUDY GUIDE? It is an aid to: • Inform students how student learnIng program of academIc sessIon has been organized • help students organIze and manage theIr studIes throughout the session • guIde students on assessment methods, rules and regulatIons THE STUDY GUIDE: • communIcates InformatIon on organIzatIon and management of the course • defInes the objectIves whIch are expected to be achIeved at the end of each topic. • IdentIfIes the learning strategies such as lectures, small group teachings, clinical skills, demonstration, tutorial and case based learning that will be implemented to achieve the objectives. • provIdes a lIst of learnIng resources such as books, computer assIsted learning programs, web- links, for students to consult in order to maximize their learning. 3 1. Learning objectives (at the end of each topic) 2. Sources of knowledge: i. Recommended Books 1. Basic and Clinical Pharmacology by Katzung, 13th Ed., Mc Graw-Hill 2. Pharmacology by Champe and Harvey, 2nd Ed., Lippincott Williams & Wilkins ii. CDs of Experimental Pharmacology iii. CDs of PHARMACY PRACTICALS iv. Departmental Library containing reference books & Medical Journals v. GENERAL PHARMACOLOGY DFINITIONS vi. CLASSIFICATIONS OF PHARMACOLOGY vii.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]